Shopping Cart

Your shopping cart is currently empty

DBCO-PEG4-GGFG-Dxd

Name: DBCO-PEG4-GGFG-Dxd
Brand: TargetMol
SKU: T84734
Price: 289 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T84734Cas No. 2694856-51-2

DBCO-PEG4-GGFG-Dxd is an ADC linker-payload intermediate used for synthesizing antibody-drug conjugates. This product consists of the DNA topoisomerase I inhibitor Dxd (Deruxtecan) conjugated to a cleavable GGFG tetrapeptide-based linker. The terminal DBCO group functions as a click chemistry handle, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules for the efficient construction of tumor-targeted ADCs.

DBCO-PEG4-GGFG-Dxd

😃Good

Purity: 96.58%

Catalog No. T84734Cas No. 2694856-51-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$289	-	In Stock
5 mg	$689	-	In Stock
10 mg	$1,180	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:96.58%

ee:100%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS FNMR

Product Introduction

Bioactivity

Description	DBCO-PEG4-GGFG-Dxd is an ADC linker-payload intermediate used for synthesizing antibody-drug conjugates. This product consists of the DNA topoisomerase I inhibitor Dxd (Deruxtecan) conjugated to a cleavable GGFG tetrapeptide-based linker. The terminal DBCO group functions as a click chemistry handle, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules for the efficient construction of tumor-targeted ADCs.
In vitro	In biochemical and cell-based conjugation assays, DBCO-PEG4-GGFG-Dxd exhibits rapid and specific reactivity with azide-functionalized antibodies, forming stable ADCs that release the active Dxd payload upon lysosomal cathepsin-mediated cleavage of the GGFG peptide linker, resulting in potent cytotoxicity against topoisomerase I-expressing cancer cells [1].
In vivo	In pharmacological studies using tumor-bearing mouse models, the administration of ADCs synthesized using DBCO-PEG4-GGFG-Dxd leads to a significant, dose-dependent inhibition of tumor growth and prolonged survival; the GGFG linker ensures systemic stability while allowing efficient intratumoral release of Dxd, demonstrating the potential for targeted delivery and reduced off-target toxicity in preclinical cancer therapy research [1].

Chemical Properties

Molecular Weight	1375.45
Formula	C₇₂H₇₉FN₁₀O₁₇
Cas No.	2694856-51-2
Smiles	N(C(COCNC(CNC([C@H](CC1=CC=CC=C1)NC(CNC(CNC(CCOCCOCCOCCOCCNC(CCC(=O)N2C=3C(C#CC=4C(C2)=CC=CC4)=CC=CC3)=O)=O)=O)=O)=O)=O)=O)[C@@H]5C6=C7C(C=8N(C7)C(=O)C9=C(C8)[C@](CC)(O)C(=O)OC9)=NC=%10C6=C(CC5)C(C)=C(F)C%10

Storage & Solubility Information

Storage

store at low temperature,The compound is unstable in solution. Please use soon | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 40 mg/mL (29.08 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	0.7270 mL	3.6352 mL	7.2703 mL	36.3517 mL
5 mM	0.1454 mL	0.7270 mL	1.4541 mL	7.2703 mL
10 mM	0.0727 mL	0.3635 mL	0.7270 mL	3.6352 mL
20 mM	0.0364 mL	0.1818 mL	0.3635 mL	1.8176 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc